Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPR-6023021 Injection in Advanced Solid Tumors With Bone Metastases
CTR20254494Phase 2Active
- Sponsor
- Chengdu Xinke Pharmaceutical Co., Ltd.
- Start
- Nov 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BPR-6023021 in Nonhematologic neoplasms, sponsored by Chengdu Xinke Pharmaceutical Co., Ltd.. Started Nov 2025; status: active.
02
Drugs
BPR-6023021
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20254494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254494.